Clinical Trial: Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863506) titled 'Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC' on March 03.

Brief Summary: This is a prospective, multi-cohort, single-arm Phase II clinical trial evaluating the efficacy and safety of befotertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR non-classical mutations.

The study comprises two independent cohorts:

Cohort 1: Patients with EGFR uncommon mutations (G719X, L861Q, or S768I). Cohort 2: Patients with EGFR exon 20 insertion mutation

Primary endpoint: Objective response rate (ORR) assessed by RE...